H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Liquidia Technologies today and set a price target of $35.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Andrew Fein’s rating is based on several promising developments within Liquidia Technologies. Firstly, the company is experiencing strong sales momentum with its product Yutrepia, supported by favorable prescription trends and payer dynamics, which suggests a successful first quarter. Additionally, Liquidia is on track to achieve cash-flow positivity and profitability sooner than expected, thanks to disciplined cost management and operational efficiencies.
Moreover, the upcoming R&D Day is anticipated to highlight the L606 program, showcasing new data that could enhance the company’s value and demonstrate its clinical development capabilities. Lastly, despite ongoing patent litigation with United Therapeutics, management remains optimistic about a favorable resolution, which could further benefit Liquidia. These factors collectively contribute to a positive outlook for the company’s growth and profitability, justifying the Buy rating.
Fein covers the Healthcare sector, focusing on stocks such as Palvella Therapeutics, United Therapeutics, and KalVista Pharmaceuticals. According to TipRanks, Fein has an average return of 23.0% and a 53.88% success rate on recommended stocks.
In another report released on September 29, LifeSci Capital also maintained a Buy rating on the stock with a $54.00 price target.